PAR 5.00% 19.0¢ paradigm biopharmaceuticals limited..

Ann: POSITIVE TOP-LINE RESULTS FROM PRECLINICAL STUDY IN ARDS, page-58

  1. 585 Posts.
    lightbulb Created with Sketch. 64
    Hmm - seems I can't post links...


    Anyway, PAR announced in the JUNE QUARTERLY ACTIVITIES REPORT on 29th July 2021:
    • New Patents: During the quarter, Paradigm filed two additional patents for the use of
    PPS in Acute Respiratory Distress Syndrome (ARDS).

 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.